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Mitochondria of normal eukaryotic cells synthesize most ATP requirements 
needed to support cellular activity. They also participate in Ca2+ and reactive oxygen 
species (ROS) signaling and in the execution of cell death. The structure and molecular 
composition of mitochondria vary largely among the different cellular types of 
mammals1. The final mitochondrial phenotype results from gene expression programs 
that are regulated at both the transcriptional2 and post-transcriptional3 levels.   
A key component of mitochondria in energy conservation, ROS signaling and 
the execution of cell death is the H+-ATP synthase, a reversible engine of oxidative 
phosphorylation that catalyzes the synthesis of ATP using as driving force the proton 
gradient generated by the respiratory chain4 (Fig. 1A). Its catalytic subunit (β-F1-
ATPase, dark blue in Fig. 1) forms part of the soluble F1-ATPase domain (Fig. 1A). β-
F1-ATPase is significantly diminished in cancer and provides a bioenergetic signature 
of disease progression and of the response to chemotherapy5. In carcinomas of the lung, 
colon and breast the down-regulation of β-F1-ATPase is also accompanied by an 
increased expression of the ATPase Inhibitory Factor 1 (IF1)6, a physiological inhibitor 
of the H+-ATP synthase7. 
IF1 is a highly conserved protein encoded in the nuclear ATPIF1 gene. 
Alternative splicing generates three different isoforms of IF1. The expression of IF1 in 
different normal human tissues has been shown to vary largely6, from very high levels 
in the heart, to intermediate expression in the liver and negligible levels in breast, colon 
and lung. In contrast, mitochondria of prevalent human carcinomas have an 
overwhelming content of IF16.   
The physiological function of IF1 in normal hypoxic cells is to inhibit the 
hydrolase activity of the H+-ATP synthase7, i.e., its reverse functioning when 
mitochondrial matrix pH drops below neutrality. In this situation, residues 48 to 56 
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stabilize the formation of a coiled-coil region between two IF1 molecules to generate 
the active IF1 inhibitory dimmer. The structure of the inhibited F1-ATPase complex 
with bound IF1 in the presence of ATP has been solved8. Residues 1-13 in IF1 stabilize 
the binding of the inhibitor to the αβ-interface in the F1-ATPase domain, blocking 
rotary catalysis of the H+-ATP synthase8.  
More recently, we have described that over-expression of IF1 in cells with 
negligible content of the protein results in the inhibition of the ATP synthetic activity of 
the H+-ATP synthase and the switch to an increased aerobic glycolysis6, 9 (Fig. 1B). On 
the contrary, silencing of IF1 enhances the H+-ATP synthase activity and reduces 
aerobic glycolysis6, 9. These findings strongly support that IF1 is a master regulator of 
energy metabolism playing a crucial role in mediating the metabolic switch experienced 
by cancer cells in order to favor the diversion of carbon skeletons for biosynthetic 
processes (Fig. 1B).  
How is IF1 up-regulated in cancer?  The answer to this question is presently 
unknown. One can speculate that hypoxia, activating mutations in cancer genes or other 
epigenetic events of the tumor microenvironment might directly control the expression 
of IF1. In any case, it is likely that different cell-type specific programs of gene 
regulation will mediate IF1 accretion in different carcinomas.  
An additional question that deserves further investigation is why the high over-
expression of IF1 in some normal human tissues is not blocking by mass-action ratio the 
synthase activity of the H+-ATP synthase. One can speculate that a mechanism of post-
translational modification exists in addition to the well-known pH regulated binding of 
IF1 to F1-ATPase7. Such a mechanism should override the inhibition promoted by the 
very high content of IF1 in these tissues. In this situation, it is likely that the carcinomas 
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that over-express IF1 either lack this sort of regulation and/or the mechanism results 
inactivated by oncogenesis.  
Moreover, and in addition to the role of IF1 in rewiring energy metabolism (Fig. 
1B), the over-expression of IF1 in human cancer cells also triggers a retrograde signal to 
the nucleus to establish the appropriate adaptive cellular program needed for tumor 
development9 (Fig. 1B). Indeed, IF1-mediated inhibition of the H+-ATP synthase results 
in mitochondrial hyperpolarization (Fig. 1B) and the subsequent production of 
superoxide radical9 (ROS in Fig. 1B). Remarkably, it has been demonstrated that the 
ROS-mediated response in colon cancer cells signals to the nucleus an NF-κB-
dependent adaptation that includes enhanced proliferation, invasion and cell survival9. 
Conversely, permanent IF1-knockdown in HeLa cells triggers an increase in cell death 
response when exposed to ischemia or high ROS10. Overall, IF1 is the mitochondrial 
factor that contributes to the acquisition of other hallmarks of the cancer phenotype. 
Due to the heterogeneity of mitochondria in mammals, we anticipate that the 
development of conditional and tissue-specific IF1 transgenic mouse models will 
contribute to unveil the specific mechanism of action of IF1 in different cellular types. 
Experiments in this regard are already in their way.  
Finally, we stress that new insights into the mechanisms that regulate the 
expression and/or activity of IF1 will open-up a promising venue for the development of 
a targeted treatment of cancer metabolism, short-cutting in this way the winding trail 
that we are experiencing to successfully translate basic cancer knowledge into the 
clinics.  
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Figure legend 
 
Figure 1. IF1 regulates energy metabolism in cancer cells. A, In normal aerobic cells 
the oxidation of glucose to CO2 and H2O is the source of electrons (e-) that feeds the 
respiratory chain (RC) for the generation of the proton gradient (H+, green). In oxidative 
phosphorylation, the H+-ATP synthase (F0, yellow rotor and F1, blue membrane 
protruding head) uses the proton gradient for the synthesis of ATP. The H+-ATP 
synthase supplies most of the ATP needed to sustain cellular activity. In the presence of 
oxygen the production of lactate (aerobic glycolysis) is low. B, The over-expression of 
IF1 in cancer cells inhibits the H+-ATP synthase and limits the flux of ATP being 
synthesized in oxidative phosphorylation. Consequently, aerobic glycolysis is 
stimulated and glucose derived carbon skeletons are diverted for biosynthetic purposes. 
In cancer cells, the oxidation of pyruvate in mitochondria is restrained. Inhibition of the 
H+-ATP synthase promotes an increase in the mitochondrial membrane potential (H+, 
green) and the subsequent production of superoxide radical (ROS, red). Mitochondrial 
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ROS signal to the nucleus of the cell features of the cancer phenotype such as the 
promotion of proliferation, invasion and survival. The oxidation of glutamine in cancer 
cells is not taken into consideration for simplicity of the schematic. ANT, adenine 
nucleotide translocase. 
 
 
 
 
 
